We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    EFC16819
Previous Study | Return to List | Next Study

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04751487
Recruitment Status : Recruiting
First Posted : February 12, 2021
Last Update Posted : December 2, 2022
Sponsor:
Collaborator:
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Sanofi

Brief Summary:

Primary Objective:

Primary population (former smokers cohort):

  • Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD

Secondary Objectives:

Primary population (former smokers cohort):

  • Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former smokers with moderate-to-severe COPD
  • Evaluate the efficacy of itepekimab compared with placebo on occurrence of acute exacerbation of COPD (AECOPD) in former smokers with moderate-to-severe COPD
  • Evaluate the efficacy of itepekimab compared with placebo on severe AECOPD in former smokers with moderate-to-severe COPD
  • Evaluate the efficacy of itepekimab compared with placebo on corticosteroid-treated AECOPD in former smokers with moderate-to-severe COPD
  • Evaluate the efficacy of itepekimab compared with placebo on respiratory symptoms in former smokers with moderate-to-severe COPD
  • Evaluate the efficacy of itepekimab compared with placebo on Forced Expiratory Volume in 1 second (FEV1) slope in former smokers with moderate-to-severe COPD
  • Evaluate the efficacy of itepekimab compared with placebo on health-related quality of life (HRQoL) as assessed by St. George's Respiratory Questionnaire (SGRQ) in former smokers with moderate-to-severe COPD
  • Evaluate the safety and tolerability of itepekimab in former smokers with moderate-to-severe COPD
  • Evaluate the pharmacokinetic (PK) profile of itepekimab in former smokers with moderate-to-severe COPD
  • Evaluate immunogenicity to itepekimab in former smokers with moderate-to-severe COPD

Secondary population (current smokers cohort)

  • Estimate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate or severe COPD exacerbations in current smokers with moderate-to-severe COPD
  • Estimate the efficacy of itepekimab compared with placebo on pulmonary function in current smokers with moderate-to-severe COPD
  • Estimate the safety and tolerability of itepekimab in current smokers with moderate-to-severe COPD
  • Estimate the PK profile of itepekimab in current smokers with moderate to severe COPD
  • Estimate immunogenicity to itepekimab in current smokers with moderate-to-severe COPD

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Drug: Itepekimab SAR440340 Drug: Placebo Phase 3

Detailed Description:

The study duration per participant:

  • Screening period is 3-5 weeks
  • Randomized investigational medicinal product (IMP) treatment period is 52 weeks for first cohort of randomized former smoker participants [approximately 930] and cohort of current smokers [approximately 280], and 24 to 52 weeks for potential additional randomized former smoker participants
  • Post-IMP treatment follow-up period is 20 weeks

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1210 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Actual Study Start Date : February 12, 2021
Estimated Primary Completion Date : August 26, 2024
Estimated Study Completion Date : January 13, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Arm Intervention/treatment
Experimental: Itepekimab Q2W in former smokers
Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for up to 52 weeks
Drug: Itepekimab SAR440340
Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
Other Name: REGN3500

Experimental: Itepekimab Q4W in former smokers
SC administration of Itepekimab every 4 weeks (Q4W) for up to 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP
Drug: Itepekimab SAR440340
Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
Other Name: REGN3500

Placebo Comparator: Placebo in former smokers
SC administration of matching placebo Q2W for up to 52 weeks
Drug: Placebo
Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous

Experimental: Itepekimab Q2W in current smokers
SC administration of Itepekimab every 2 weeks (Q2W) for 52 weeks
Drug: Itepekimab SAR440340
Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
Other Name: REGN3500

Placebo Comparator: Placebo in current smokers
SC administration of matching placebo Q2W for 52 weeks
Drug: Placebo
Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous




Primary Outcome Measures :
  1. Annualized rate of moderate or severe acute exacerbation of COPD (AECOPD) in former smokers [ Time Frame: Baseline up to End Of Treatment (EOT) (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants) ]
    Annualized rate of moderate or severe acute exacerbation of COPD (AECOPD) over the placebo-controlled treatment period.


Secondary Outcome Measures :
  1. Change from baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) in former smokers [ Time Frame: Baseline to Week 24 ]
    FEV1 is the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

  2. Change from baseline in post-BD FEV1 in former smokers [ Time Frame: Baseline to Week 24 and Week 52 ]
    FEV1 is the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

  3. Change from baseline in pre-BD FEV1 in former smokers [ Time Frame: Baseline to Week 52 ]
    FEV1 is the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

  4. Time to first moderate or severe AECOPD in former smokers [ Time Frame: Baseline through EOT (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants) ]
    Time to first moderate or severe AECOPD over the placebo-controlled treatment period.

  5. Annualized rate of severe AECOPD in former smokers [ Time Frame: Baseline up to EOT (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants) ]
    Annualized rate of severe AECOPD over the placebo-controlled treatment period.

  6. Time to first severe AECOPD in former smokers [ Time Frame: Baseline through EOT (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants) ]
    Time to first severe AECOPD over the placebo-controlled treatment period.

  7. Annualized rate of corticosteroid-treated AECOPD in former smokers [ Time Frame: Baseline up to EOT (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants) ]
    Annualized rate of corticosteroid-treated AECOPD over the placebo-controlled treatment period.

  8. Change from baseline in Evaluating Respiratory Symptoms in COPD (E-RS:COPD) total score in former smokers [ Time Frame: Baseline to Week 24 and Week 52 ]
    The E-RS: COPD is administered as a part of the 14-item EXACT questionnaire and is completed on a daily basis.The 11-item E-RS:COPD assesses severity of respiratory symptoms overall and severity of individual symptoms such as breathlessness, cough and sputum, and chest symptoms The total score of E-RS:COPD ranges from 0 to 40, with higher values indicating more severe respiratory symptoms.

  9. Rate of change in post-BD FEV1 (L) from baseline (post-BD FEV1 slope) in former smokers [ Time Frame: Baseline up to EOT (Week 52 for initial randomized participants, 24 to 52 weeks for potential additional randomized former smoker participants) ]
  10. Change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score in former smokers [ Time Frame: Baseline to Week 24 and Week 52 ]
    The SGRQ is a 50-item questionnaire designed to measure and quantify health status in adult participants with chronic airflow limitation. A global score ranges from 0 to 100. Scores by dimension are calculated for 3 domains: Symptoms, Activity and Impacts (Psycho-social) as well as a total score. A lower score indicates better quality of life.

  11. Proportion of participants with a decrease from baseline of at least 4 points in SGRQ total score in former smokers [ Time Frame: Baseline to Week 24 and Week 52 ]
    The SGRQ is a 50-item questionnaire designed to measure and quantify health status in adult participants with chronic airflow limitation. A global score ranges from 0 to 100. Scores by dimension are calculated for 3 domains: Symptoms, Activity and Impacts (Psycho-social) as well as a total score. A lower score indicates better quality of life.

  12. Incidence of treatment-emergent adverse events (TEAEs), adverse event of special interests (AESIs), serious adverse events (SAEs), and adverse events (AEs) leading to permanent treatment discontinuation in former smokers [ Time Frame: Baseline up to End Of Study (EOS) (Week 72 for initial randomized participants, 44 to 72 weeks for potential additional randomized former smoker participants) ]
  13. Incidence of potentially clinically significant laboratory test, vital signs, and electrocardiogram (ECGs) abnormalities in former smokers [ Time Frame: Baseline up to EOS (Week 72 for initial randomized participants, 44 to 72 weeks for potential additional randomized former smoker participants) ]
  14. Functional itepekimab concentrations in serum in former smokers [ Time Frame: Baseline up to EOS (Week 72 for initial randomized participants, 44 to 72 weeks for potential additional randomized former smoker participants) ]
  15. Incidence of treatment-emergent anti-itepekimab antibodies responses in former smokers [ Time Frame: Baseline up to EOS (Week 72 for initial randomized participants, 44 to 72 weeks for potential additional randomized former smoker participants) ]
  16. Annualized rate of moderate or severe AECOPD in current smokers [ Time Frame: Baseline up to Week 52 ]
    Annualized rate of moderate or severe AECOPD over the placebo-controlled treatment period.

  17. Change from baseline in pre-BD FEV1 in current smokers [ Time Frame: Baseline up to Week 24 and Week 52 ]
    FEV1 is the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

  18. Incidence of TEAEs, AESIs, SAEs, and AEs leading to permanent treatment discontinuation in current smokers [ Time Frame: Baseline up to EOS (Week 72) ]
  19. Incidence of potentially clinically significant laboratory, vital signs, and ECGs abnormalities in current smokers [ Time Frame: Baseline up to EOS (Week 72) ]
  20. Functional itepekimab concentrations in serum in current smokers [ Time Frame: Baseline up to EOS (Week 72) ]
  21. Incidence of treatment-emergent anti-itepekimab antibodies responses in current smokers [ Time Frame: Baseline up to EOS (Week 72) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria :

  • Participant must be 40 to 85 years of age inclusive.
  • Physician diagnosis of COPD for at least 1 year (based on Global Initiative for Chronic Obstructive Lung Disease [GOLD] definition).
  • Smoking history of ≥10 pack-years:

    • For former smokers: participants who report that they are not currently smoking and smoking cessation must have occurred ≥6 months prior to Screening (Visit 1A) with an intention to quit permanently.
    • For current smokers: participants who report that they are currently smoking tobacco (participant smoked at least 1 cigarette per day on average during the past 7 days) at Screening (Visit 1A) and who are not currently participating in or planning to initiate a smoking cessation intervention at Screening (Visit 1A) or during Screening period.
  • Participants with moderate-to-severe COPD
  • Participant-reported history of signs and symptoms of chronic bronchitis (chronic productive cough for at least 3 months in the year prior to Screening in a participant in whom other causes of chronic cough [eg, inadequately treated gastroesophageal reflux or chronic rhinosinusitis; or clinical diagnosis of bronchiectasis] has been excluded).
  • Documented history of high exacerbation risk defined as having had ≥2 moderate or ≥1 severe exacerbations within the year prior to Screening (Visit 1A), with at least 1 exacerbation treated with systemic corticosteroids. At least one exacerbation must have occurred while participants were on their current controller therapy:

    • Moderate exacerbations will be recorded by the Investigator and are defined as acute worsening of respiratory symptoms that requires either systemic corticosteroids (IM, IV, or oral) and/or antibiotics.
    • Severe exacerbations will be recorded by the Investigator and are defined as AECOPD that require hospitalization or observation for >24 hours in emergency department/urgent care facility.
  • Participants with standard of care controller therapy, for ≥3 months prior to Screening (Visit 1A) and at a stable dose of controller therapy for at least 1 month prior to the Screening, including either: inhaled corticosteroid (ICS) + long-acting beta-agonist (LABA), long-acting muscarinic antagonist (LAMA) + LABA or LAMA + LABA + ICS.
  • Body mass index (BMI) ≥18.0 kg/m^2, or BMI ≥16.0 kg/m^2 for participants enrolled in East-Asian countries.
  • Female participant is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    • not a women of child-bearing potential (WOCBP) OR
    • a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 20 weeks after the last dose of study intervention. -

Exclusion criteria:

  • Current diagnosis of asthma according to the Global Initiative for Asthma (GINA) guidelines, or documented history of asthma unless asthma resolved before 18 years of age and has not recurred.
  • For former smokers: Active smoking or vaping of any products (eg, nicotine, tetrahydrocannabinol [THC]) within 6 months prior to Screening (Visit 1A).
  • For current smokers: vaping of any products (eg, nicotine, THC) within 6 months prior to Screening (Visit 1A).
  • Clinically significant new abnormal electrocardiogram (ECG) within 6 months prior to, or at Screening (Visit 1A) that may affect the participant's participation in the study.
  • Clinically significant and current pulmonary disease other than COPD, eg, sarcoidosis, interstitial lung disease, bronchiectasis (clinical diagnosis), diagnosis of α-1 anti-trypsin deficiency, or another diagnosed pulmonary disease.
  • Diagnosis of cor pulmonale, evidence of right cardiac failure, or moderate-to-severe pulmonary hypertension.
  • Hypercapnia requiring bilevel positive airway pressure (BiPAP).
  • Moderate or severe exacerbation of COPD (AECOPD) within 4 weeks prior to Screening (Visit 1A).
  • Prior history of / planned: lung pneumonectomy for any reason, or lung volume reduction procedures (including bronchoscopic volume reduction) for COPD. Note: Surgical biopsy, or segmentectomy, or wedge resection, or lobectomy for other diseases would not be excluded.
  • Unstable ischemic heart disease, including acute myocardial infarction within the past 1 year prior to Screening, or unstable angina in the 6 months prior to Screening (Visit 1A).
  • Cardiac arrhythmias including paroxysmal (eg, intermittent) atrial fibrillation.
  • Uncontrolled hypertension (ie, systolic blood pressure [BP] >180 mm Hg or diastolic BP >110 mm Hg with or without use of anti-hypertensive therapy).
  • Participants with active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection (TBI), or who are at high risk of contracting TB (such as close contact with individuals with active or latent TB) or received Bacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior to Screening (Visit 1A).
  • History of human immunodeficiency virus (HIV) infection or positive HIV 1/2 serology at Screening (Visit 1A).
  • Suspicion of, or confirmed, coronavirus disease 2019 (COVID-19) infection or in contact with known exposure to COVID-19 at Screening (Visit 1A); known history of COVID-19 infection within 4 weeks prior to Screening (Visit 1A); history of requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO) secondary to COVID-19 within 3 months prior to Screening (Visit 1A); participants who have had a COVID-19 infection prior Screening (Visit 1A) who have not yet sufficiently recovered to participate in the procedures of a clinical trial.
  • Evidence of acute or chronic infection requiring systemic treatment with antibacterial, antiviral, antifungal, antiparasitic, or antiprotozoal medications within 4 weeks before Screening (Visit 1A), significant viral infections within 4 weeks before Screening (Visit 1A) that may not have been treated with antiviral treatment (eg, influenza receiving only symptomatic treatment).
  • Participants with active autoimmune disease or participants using immunosuppressive therapy for autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis.
  • History of malignancy within 5 years before Screening (Visit 1A), except completely treated in situ carcinoma of the cervix, completely treated and resolved nonmetastatic squamous or basal cell carcinoma of the skin.
  • Previous use of itepekimab.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04751487


Contacts
Layout table for location contacts
Contact: Trial Transparency email recommended (Toll free number for US & Canada) 800-633-1610 ext option 6 Contact-US@sanofi.com

Locations
Show Show 224 study locations
Sponsors and Collaborators
Sanofi
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT04751487    
Other Study ID Numbers: EFC16819
2020-001819-24 ( EudraCT Number )
U1111-1250-2843 ( Other Identifier: UTN )
First Posted: February 12, 2021    Key Record Dates
Last Update Posted: December 2, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases